PPARG and fatty liver disease: In vitro studies suggest that AX has the potential to protect against liver steatosis by preventing fat accumulation in hepatocytes [866,867], It has been reported that AX may reduce hepatic lipid accumulation by modulating the activity of nuclear receptors PPAR-α and PPAR-γ in a favorable manner, acting as a PPAR-α agonist and a PPAR-γ antagonist, respectively [866].